SIDBI Venture Capital funds OmniBRx Biotechnologies Private Limited

New Delhi :  Bioprocess engineering firm OmniBRx  has raised INR 30 crore ($4.8 million) in Series A funding from SIDBI Venture Capital Limited.

Commenting on the occasion, Mr. Ravindra Patel, founder and CEO of OmniBRx Biotechnologies, said, “We are thankful to the team at SVCL for believing in our vision and backing us on our expansion plans”. Even more, he elaborated on “Production of vaccines and other biologicals has increased worldwide demand for scalable and efficient bioprocessing technologies, particularly the Single-use bioreactor platforms. OmniBRx’s innovative technological solutions may be able to keep up with the exploding demand for biologics and vaccines.

OmniBRx’s CellBRx Single-use Bioreactors are the largest and most efficient vaccine manufacturing platform in the world, used for the mass production of vaccines and viral vectors. Ravindra chimed in, “OmniBRx is also the inventor of the first integrated seed train development platforms in close-loop sequentially programmed bioreactor systems.

Following the completion of its series A funding round, OmniBRx is prepared to aggressively enter new international markets. To increase output and keep up with rising market demands, the company plans to construct state-of-the-art manufacturing facilities and increase staff.

“We are happy to partner with OmniBRx,” said Sajit Kumar, senior vice president at SIDBI Venture Capital Limited. We anticipate that their singular attention and extensive expertise in the field will allow them to break into international markets. Our third investment from our “Ubharte Sitaare Fund,” which supports small and medium-sized enterprises (SMEs) expanding into international markets. I hope the best for them “.

OmniBRx’s sole financial adviser for the deal was Indus Capital, a boutique investment bank in Delhi that was founded by Mr. Santosh Patra.

About OmniBRx, it is an Ahmedabad-based Bioprocess engineering company focused on the design and development of novel single-use bioreactors (SUBs) for cell culture-based bioprocessing applications, i.e. Vaccines, Gene therapies, and biologics production. The Company was incorporated in 2016 and successfully launched its innovative products like CellBRx and MiniBRx single-use Bioreactor platforms.

About SIDBI Ventures, the company incorporated in 1999, is a wholly owned subsidiary of SIDBI (www.sidbi.in), the Apex Financial Institution in India for the MSME sector. Over the years, SVCL has set up and managed several Venture Capital Funds / AIFs, “Ubharte Sitaare Fund” is the eighth Fund set up and managed by SVCL.